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Many chronic diseases in humans and animals areassociated with modifications of the extracellular
matrix metabolism that lead to an accumulation of col-
lagen and the development of organ fibrosis.1 For a
long time, histologic examination of a tissue biopsy
specimen was the only available method to evaluate
organ fibrosis. The need for less invasive, more dynam-
ic, and more quantitative tests has led to the identifica-
tion of several markers of extracellular matrix
turnover, one of which is PIIINP.2 During synthesis of
type III collagen, PIIINP is cleaved off the procollagen
type III molecule in a stoichiometric manner.3 It has
been studied extensively in many human biological
fluids including serum4 and BALF5 and has been estab-
lished as a sensitive but nonspecific marker for assess-
ment of tissue collagen type III turnover.6
Procollagen type III amino terminal propeptide
has been widely investigated in several physiologic and
pathologic conditions in humans.7 In healthy children,
serum PIIINP concentration is significantly higher
than in adults and the highest values are detected dur-
ing the neonatal period.8 Serum PIIINP concentration
closely parallels the growth-velocity curve of children,
reflecting the increased collagen turnover during
growth. There are no significant sex-related differences
in serum PIIINP concentration.9 In humans, increases
in serum PIIINP concentration have been identified in
several hepatic disorders including chronic hepatitis,10
alcoholic liver disease,11 and other fibrosing disorders
such as myelofibrosis12 and systemic sclerosis.13
Increased serum PIIINP concentration has been deter-
mined in various malignancies and correlates with the
clinical extent and behavior of the tumor.14
Serum PIIINP concentration has been proven to
reliably reflect increased collagen type III turnover
associated with cardiac tissue repair and fibrosis and to
Received October 7,  2005.
Accepted November 28, 2005.
From the Departments of Small Animal Clinical Sciences,
(Schuller, Valentin, Van Israël, Clercx) and Physiology of
Reproduction (Remy), University of Liège, 4000 Liège, Belgium;
and the Laboratory of Physiology, Free University of Brussels,
1070 Brussels, Belgium (Jespers, Foulon, McEntee). Dr.
Schuller’s present address is Department for Small Animal
Clinical Studies, University College Dublin, Belfield, Dublin 4,
Ireland.
Presented in part at the 14th Congress of the European College of
Veterinary Internal Medicine, Barcelona, Spain, September 2004,
and at the 15th Congress of the European College of Veterinary
Internal Medicine, Glasgow, September 2005.
Address correspondence to Dr. Clercx.
Analytical, physiologic, and clinical validation 
of a radioimmunoassay for measurement 
of procollagen type III amino terminal 
propeptide in serum and bronchoalveolar lavage
fluid obtained from dogs
Simone Schuller, DVM; Sophie Valentin, DVM; Benoit Remy, DVM; Pascale Jespers;
Suzanne Foulon; Nicole Van Israël, DVM; Cécile Clercx, DVM, PhD; Kathleen McEntee, DVM, PhD
Objective—To validate a radioimmunoassay for mea-
surement of procollagen type III amino terminal
propeptide (PIIINP) concentrations in canine serum
and bronchoalveolar lavage fluid (BALF) and investi-
gate the effects of physiologic and pathologic condi-
tions on PIIINP concentrations.
Sample Population—Sera from healthy adult (n = 70)
and growing dogs (20) and dogs with chronic renal fail-
ure (CRF; 10), cardiomyopathy (CMP; 12), or degener-
ative valve disease (DVD; 26); and sera and BALF from
dogs with chronic bronchopneumopathy (CBP; 15) and
healthy control dogs (10 growing and 9 adult dogs).
Procedure—A radioimmunoassay was validated, and a
reference range for serum PIIINP (S-PIIINP) concentra-
tion was established. Effects of growth, age, sex,
weight, CRF, and heart failure on S-PIIINP concentra-
tion were analyzed. In CBP-affected dogs, S-PIIINP and
BALF-PIIINP concentrations were evaluated.
Results—The radioimmunoassay had good sensitivi-
ty, linearity, precision, and reproducibility and reason-
able accuracy for measurement of S-PIIINP and 
BALF-PIIINP concentrations. The S-PIIINP concentra-
tion reference range in adult dogs was 8.86 to 11.48
µg/L. Serum PIIINP concentration correlated with
weight and age. Growing dogs had significantly high-
er S-PIIINP concentrations than adults, but concentra-
tions in CRF-, CMP-, DVD-, or CBP-affected dogs were
not significantly different from control values. Mean
BALF-PIIINP concentration was significantly higher in
CBP-affected dogs than in healthy adults.
Conclusions and Clinical Relevance—In dogs, renal
or cardiac disease or CBP did not significantly affect 
S-PIIINP concentration; dogs with CBP had high BALF-
PIIINP concentrations. Data suggest that the use of
PIIINP as a marker of pathologic fibrosis might be lim-
ited in growing dogs. (Am J Vet Res 2006;67:749–755)
ABBREVIATIONS
PIIINP Procollagen type III amino terminal 
propeptide
BALF Bronchoalveolar lavage fluid
CMP Cardiomyopathy
DVD Degenerative valve disease
CRF Chronic renal failure
CBP Chronic bronchopneumopathy
ED Effective dose
IGF-I Insulinlike growth factor-I
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be of prognostic value in many conditions such as
myocardial infarction,15 as well as various types of car-
diomyopathy.16 In patients with severe congestive heart
failure, serum PIIINP concentration is closely correlat-
ed with clinical stage and outcome.17 Serum and uri-
nary PIIINP concentrations have been studied in
humans with various renal diseases18,19 as well as in
patients after renal transplantation20 and have been
shown to correlate with the extent of organ fibrosis. In
interstitial pulmonary conditions including pulmonary
fibrosis,5 acute respiratory distress syndrome21 and sar-
coidosis,22 PIIINP concentrations in both serum and
BALF are significantly increased, compared with values
in samples from healthy individuals.
The aims of the study reported here were to vali-
date a radioimmunoassay for measurement of PIIINP
in canine serum and BALF and investigate the effects of
different physiologic and pathologic conditions on 
PIIINP concentrations. The intentions were to estab-
lish a new tool for noninvasive investigation of extra-
cellular matrix turnover in dogs for both clinical and
research application and evaluate the influences of
growth, age, sex, weight, CMP, DVD, CRF, and CBP on
PIIINP concentration in canine serum and BALF.
Materials and Methods
For this study, 2 populations of dogs (overall, 172 dogs)
were used. Serum samples from 138 dogs, including healthy
adults (n = 70), healthy growing dogs (20), dogs with chron-
ic heart disease (CMP, 12; DVD, 26), and CRF (10) were col-
lected prospectively. The reference range for serum PIIINP
concentration and the influence of growth, age, weight, and
sex were examined in this group of 138 dogs. For the evalu-
ation of PIIINP concentrations in dogs with CBP, leftover
serum and BALF samples from 13 dogs with eosinophilic BP
and 2 dogs with chronic bronchitis that had participated in
another clinical trial and their respective control dogs (9
healthy adults and 10 healthy growing dogs) were used. Dogs
included in the study were owned by students, staff, or
clients of the small animal hospital of the Faculty of
Veterinary Medicine of Liège, Belgium. Fourteen healthy
adult and 11 healthy growing Beagles, belonging to the
Beagle colony of the hospital, were also included in the study.
Enrollment was based on owner consent. Dogs were consid-
ered healthy if they did not have a history of clinical disease
as reported by the owners and no abnormalities were detect-
ed during physical examination. However, further diagnostic
tests to establish their health status were not performed. In
dogs with CMP and DVD, diagnosis was made on the basis of
history; clinical signs; and compatible results of physical
examination, thoracic radiography, ECG, and echocardiogra-
phy. The diagnosis of CRF was made on the basis of history;
clinical signs; and compatible results of physical examina-
tion, blood analyses, urinalysis, and abdominal ultrasonogra-
phy. In dogs with CBP, diagnosis was made on the basis of
history, clinical signs, findings of physical examination and
thoracic radiography, and results of bronchoscopy and BALF
analysis (including cytologic and microbiologic evaluations).
Serum and BALF sample collections—Venous blood
samples were collected and placed into plastic tubes contain-
ing a separation gel.a The tubes were centrifugedb; the serum
was transferred into separate tubesc and frozen at –20°C until
analysis. The leftover serum samples from dogs with CBP
and the respective control dogs were obtained in the same
manner but frozen in the original tubes containing the sepa-
ration gel. Each BALF sample had been obtained during
bronchoscopic examination by use of a standardized method
described elsewhere.23 The BALF samples were centrifuged
immediately after retrieval and then stored at –20°C until
analysis.
Procedure for the PIIINP radioimmunoassay—Serum
and BALF concentrations of PIIINP were measured by use of
a commercially available PIIINP radioimmunoassayd that was
based on highly purified human PIIINP. The assays were per-
formed according to the procedure indicated in the instruc-
tion booklet with 3 slight modifications. The first modifica-
tion was a reduction of the volumes of samples and reagents
by 50% to increase the number of samples processed per kit.
The second modification was the introduction of supplemen-
tary dilution of the samples before centrifugation with 1 mL
of PBS solutione to facilitate aspiration of the supernatant and
reduce the concentration of iodine 125 (125I)-labeled PIIINP in
the supernatant retained in the tube after aspiration. The third
modification consisted of a slight prolongation of centrifuga-
tion time from 15 to 25 minutes and increased centrifugation
speed from 2,000 X g to 2,250 X g to achieve better separation
of supernatant and precipitate and increase the stability of the
precipitate. For analysis of BALF samples, 1 mL of BALF or
standard solution was incubated with 200 µL of 125I-tracer
solution and 100 µL of antiserum to detect small amounts of
PIIINP in the samples without further concentration.
Validation of the PIIINP radioimmunoassay—The
assay was validated by determining its sensitivity, working
range, linearity, accuracy, precision, and reproducibility.
Serial dilutions of a serum sample by use of saline (0.9%
NaCl) solutionf or the zero calibrator of the kit were per-
formed. The sample was assayed undiluted and at dilutions
of 1 in 2, 1 in 3, 1 in 4, 1 in 5, 1 in 6, 1 in 8, 1 in 10, 1 in 12,
and 1 in 16. For evaluation of parallelism of the standard
curves, concentrations of the standard solutions were plotted
with a semilogarithmic scale on the x-axis, whereas values on
the y-axis were expressed as a percentage of the maximum
binding value by use of the following equation:
B/B0 = (B–B0)•100/(Bmax–B0)
where B is the sample (or calibrator) count, B0 is the non-
specific-binding count, and Bmax is the total count. The EDs,
which are defined as the calibrator concentration corre-
sponding to 20% (ED20), 50% (ED50), and 80% (ED80) inhi-
bition of the standard curve, were determined. For evalua-
tion of dilution parallelism, the PIIINP concentrations were
plotted as a semilogarithmic curve and the observed PIIINP
concentrations were compared with the expected values.
Spiking recovery was determined by adding concentrations
of human PIIINP (1, 2.5, 5, 7.5, and 10 µg/L) to a canine
serum sample with a known PIIINP concentration (6.6
µg/L). Observed PIIINP concentrations were compared with
the expected values.
Inter- and intra-assay variabilities were determined by
use of serum samples with 3 different PIIINP concentrations
(low, 4.03 µg/L; midrange, 11.48 µg/L; and high, 15.69 µg/L).
For calculation of the intra-assay variability, each of the 3
serum samples was divided in 9 replicates. The replicates
were assayed simultaneously within the same run of the
assay. For calculation of the interassay variability, each of the
3 samples was divided in 6 replicates and assayed in consec-
utive runs of the assay during a 9-month period.
Stability of PIIINP during freezing and thawing—To
determine the stability of PIIINP in canine serum, aliquots of
samples containing 3 concentrations of PIIINP were run
through 6 freeze-thaw cycles over a period of 9 months. After
every cycle, serum PIIINP concentrations were measured and
compared with each other.
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Statistical analysis—Statistical evaluation was per-
formed by use of personal computer–based statistical soft-
ware. Normal distribution of the data was determined by pro-
ducing a normal plot. The reference range for serum PIIINP
concentration in adult dogs was established on the basis of
the 95% confidence interval for the mean serum PIIINP con-
centration in healthy adult dogs. An ANOVA, followed by an
unpaired t test, was used to evaluate the following indepen-
dent variables with regard to PIIINP concentration: weight,
age, sex, DVD, CMP, CRF, and CBP. Multivariate linear regres-
sion analysis was used to assess the relationship between
serum PIIINP concentration and weight after adjustment for
age. Serum PIIINP concentrations of dogs with heart disease
and CRF were compared with weight- and age-matched con-
trol dogs. Mean PIIINP serum concentrations were compared
between healthy growing Beagles and growing dogs of other
breeds and between adult healthy Beagles and weight- and
age-matched dogs of other breeds, given that Beagles were
overrepresented in the group of healthy dogs. Statistical sig-
nificance was defined as a value of P < 0.05. Data are
expressed as mean ± SD unless otherwise stated.
Results
Study population—One hundred seventy-two
dogs were included in the study. In each study group,
sex; breeds; and mean values of age, weight, and PII-
INP concentrations in serum and BALF were assessed
(Tables 1 and 2). In the group of dogs with heart dis-
ease, 26 dogs had DVD of the mitral (n = 23) or mitral
and tricuspid valve (3). In the group of dogs with CMP,
primary dilatated CMP was diagnosed in 11 dogs and
arrhythmogenic right ventricular CMP was diagnosed
in 1 dog. Dogs with CRF were in an advanced stage
(serum creatinine concentration > 3 mg/dL; reference
range, 0.68 to 1.45 mg/dL); proteinuria (urine protein-
to-urine creatinine ratio > 1) was identified in 2 of the
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Table 1—Signalment and mean serum PIIINP concentrations in healthy dogs and dogs with cardiac or renal disease.
Healthy Dogs with disease
Variable Adult dogs Growing dogs DVD CMP CRF
No. of dogs 70 20 26 12 10
Sex (No. of dogs)
Male/neutered male 21/9 12 13 10 7
Female/spayed female 15/13 8 1/12 1/1 1/2
Age (mean  SD 5.9  3.1 (1–15.5) 0.3  0.2 (0.1–0.6) 10.5  2.8 (4–15) 8.5  2.8 (4–12) 6.5  2.2 (3–11)
[range]; y)
Weight (mean  SD 21.1  13.5 (2.5–60) 8.4  3.4 (4.5–15) 10.8  8.6 (2.4–46) 37  15.7 (14.7–70) 31.6  5.7 (25–40)
[range]; kg)
Breeds (No. of dogs) Beagle (15) Beagle (11) Dachshund (5) Labrador Retriever (3) Belgian Shepherd 
Mixed (14) Labrador Retriever (2) Maltese (5) Mixed (2) Dog (2)
Yorkshire Terrier (5) Mixed (2) Poodle (4) Great Dane (1) Labrador Retriever (2)
Labrador Retriever (4) Other purebreds (5) Mixed (3) Cocker Spaniel (1) Bernese Mountain 
Dachshund (3) Other purebreds (9) Boxer (1) Dog (2)
Griffon Kortals (3) German Shepherd Mixed (2)
German Shepherd Dog (3) Dog (1) Other purebreds (2)
Other purebreds (23) Newfoundland (1)
Other purebreds (2)
Serum PIIINP
(mean  SD [range]; 10.2  5.5 (2.5–26.1) 106.8  67.9 (17.7–252) 10.5  2.8 (2.5–15.5) 9.6  2.8 (6.5–14.8) 14.9  1.5 (8–23.1)
µg/L)
Table 2—Signalment and mean PIIINP concentrations in serum and BALF in healthy adult and grow-
ing dogs and dogs with CBP.
Healthy Dogs with disease 
Variable Adult dogs Growing dogs CBP
No. of dogs 9 10 16
Sex (No. of dogs)
Male/neutered male 6/0 5/0 5/2
Female/spayed female 2/1 5/0 5/4
Age (mean  SD [range]; y) 7.5  1.7 (6–10) 0.7  0.1 (0.7–1.0) 4.6  3.1 (1–10)
Weight (mean  SD [range]; kg) 18.1  7.6 (13–35) 13.0  9.5 (10–40) 29.2  10.6 (5.4–45)
Breeds (No. of dogs) Beagle (5) Beagle (9) Labrador Retriever (5)
Husky (1) Newfoundland (1) Golden Retriever (2)
Cocker Spaniel (1) Jack Russell Terrier (2)
Labrador  Retriever(1) Mixed (2)
Mixed (1) Bearded Collie (1)
Giant Schnauzer (1)
German Shepherd Dog (1)
Husky (1)
Rottweiler (1)
PIIINP concentration (mean  SD
[range]; µg/L)
Serum 10.9  7.4 (0.1–23.6) 17.5  7.45 (6.1–31.7) 11.8  6.3 (2.9–27.3)
BALF 0.4  0.8 (0–2.14) 2.3  1.1 (0–3.67) 16.2  33.8 (0–129.6) 
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10 dogs in this group. In the group of dogs with CBP,
13 dogs had evidence of eosinophilic BP and chronic
bronchitis was diagnosed in 2 dogs.
Validation of the PIIINP radioimmunoassay—
Standard inhibition curves of human standard solu-
tions and serial dilutions of a canine serum sample
were similar and had good linearity and parallelism
(Figure 1). The ED20, ED50, and ED80 were 17.49 µg/L,
4.4 µg/L, and 0.99 µg/L, respectively. Reproducible lin-
ear results for the logarithmically transformed dilution
curves were obtained. Strong correlation was deter-
mined between measured and calculated values for
both diluents, saline solution and zero calibrator
(Figure 2). The observed-to-expected ratio for spiking
recovery ranged from 87% to 121% (mean ± SD recov-
ery, 114.1 ± 7.14%). In 3 serum samples with low,
midrange, or high PIIINP concentration, coefficients of
variation for intra-assay variability were 5.34%, 6.42%,
and 5.82%, respectively, and coefficients of variation
for interassay variability were 24.74%, 5.68%, and
15.71%, respectively. Serum PIIINP concentrations of 3
samples did not vary significantly (P = 0.5) when run
through 6 freeze-thaw cycles.
Serum PIIINP concentrations in healthy dogs—
The reference range for serum PIIINP concentration in
healthy adult dogs was 8.27 to 11.7 µg/L (mean, 9.894
µg/L [SD, 5.06 µg/L; SEM, 0.609 µg/L]). Mean serum
PIIINP concentration was significantly (P < 0.01)
higher in growing dogs (0 to 8 months old) than in
adult dogs (> 12 months old). Mean serum PIIINP
concentrations were highest in dogs < 2 months old
(208.79 ± 32.3 µg/L) and decreased by 50% at the age
of 4 months (100.07 ± 24.3 µg/L). A further 50%
decrease was detected at the age of 8 months (54.57 ±
21.3 µg/L). There was a mild negative correlation
between age and serum PIIINP concentration (R2 =
0.121; P < 0.05) and a positive correlation between
weight and serum PIIINP concentration (R2 = 0.345; P
< 0.001). No correlation was evident between sex and
serum PIIINP concentration. Mean serum PIIINP con-
centration was not significantly (P = 0.72) different
between growing Beagles (76.46 ± 15.71 µg/L) and
growing dogs of other breeds (70.09 ± 9.53 µg/L) nor
between adult healthy Beagles (6.20 ± 0.99 µg/L) and
weight- and age-matched healthy dogs of other breeds
(6.98 ± 0.63 µg/L; P = 0.51).
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Figure 1—Dilution curve of a canine serum sample diluted with
saline (0.9% NaCl) solution (triangles) or the zero calibrator
(squares) provided in the kit of a commercially available radio-
immunoassay for PIIINP. The results are plotted as semilogarith-
mic curve. Notice the strong correlation between the measured
and calculated PIIINP values for samples diluted with the zero
calibrator or saline solution.
Figure 2—Parallelism of standard inhibition curves of a canine
serum sample diluted with saline solution (triangles) or the zero
calibrator (squares) provided in the kit of a commercially avail-
able radioimmunoassay for PIIINP. Good linearity and strong cor-
relation between calibration curve (diamonds) and standard inhi-
bition curves for samples diluted with the zero calibrator or
saline solution. B = Sample (or calibrator) count. B0 =
Nonspecific-binding count.
Figure 3—Comparison of PIIINP concentrations in BALF sam-
ples collected from 9 healthy adult dogs, 10 healthy growing
dogs, and 15 dogs with CBP. Mean BALF PIIINP concentration
was significantly higher in growing dogs than in healthy adult
dogs. Mean BALF PIIINP concentration was significantly higher
in dogs with CBP than in healthy adult dogs. There was no sig-
nificant difference in mean BALF PIIINP concentration between
dogs with CBP and healthy growing dogs. A value of P < 0.05
was considered significant.
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Serum PIIINP concentrations in dogs with heart
disease and CRF—There were no significant differ-
ences in serum PIIINP concentration in dogs with
DVD, CMP, or CRF, compared with weight- and age-
matched control dogs.
Serum and BALF PIIINP concentrations in dogs
with CBP—Serum PIIINP concentration in dogs with
CBP was not significantly different from that of adult
control dogs, but the difference in serum PIIINP con-
centration between dogs with CBP and healthy grow-
ing dogs was significant. Mean PIIINP concentration in
BALF was significantly higher in healthy growing dogs
than in healthy adults (Figure 3). Mean PIIINP con-
centration in BALF of dogs with CBP was significantly
higher than the value in healthy adult dogs, but not
significantly different from mean BALF PIIINP concen-
tration in growing dogs. Procollagen type III amino ter-
minal propeptide was undetectable in BALF samples
from 7 of 9 healthy adult dogs and from only 3 of 16
dogs with CBP. Nevertheless, there was considerable
overlap between the 2 groups.
Discussion
Procollagen type III amino terminal propeptide is
considered a sensitive but nonspecific marker for
assessment of tissue collagen III metabolism in
humans.6 The aims of the present study were to validate
a commercially available radioimmunoassay that was
based on highly purified human PIIINP for use in dogs
and to investigate the effects of different physiologic
and pathologic conditions on PIIINP concentration in
canine serum and BALF. The radioimmunoassay used is
very sensitive and precise for measurement of PIIINP in
many human biological fluids including serum9 and
BALF.22 The results of the present study indicated that
the assay has good sensitivity, linearity, and repro-
ducibility and acceptable accuracy for measurement of
PIIINP in canine serum. Good cross-reactivity between
human and canine PIIINP could be expected, given that
collagen synthesis and metabolism are known to be
well preserved throughout many mammalian species.24
Spiking recovery was 87% to 121% (mean recov-
ery, 114.1 ± 7.14%), which we consider a satisfactory
result. Intra- and interassay variations are indicators of
assay precision, and coefficients of variation < 10% to
15% are usually set as an acceptable standard. In the
present study, the intra-assay coefficient of variation
for the 9 replicates of the 3 samples containing low,
midrange, or high PIIINP concentration were < 7%,
indicating excellent precision. The interassay coeffi-
cients of variation for the 6 replicates of the same 3
samples were 5.68% for the midrange PIIINP concen-
tration and 15.71% for the high PIIINP concentration,
but 24.7% for the low PIIINP concentration, which
might indicate limited precision at the low and the
high working ranges of the assay. However, in our
opinion, the overall precision of the assay can still be
considered good. Furthermore, serum PIIINP concen-
trations were not significantly altered after 6 freeze-
thaw cycles; these results correspond with findings for
human PIIINP, which is considered to be very stable in
serum.25
Among the dogs used in our study, there were no
sex-related differences in serum PIIINP concentrations;
however, the influence of neutering on serum PIIINP
concentration remains to be analyzed. The serum 
PIIINP concentration in Beagles was not significantly
different from that in other breeds. Mean serum PIIINP
concentration was approximately 10 to 20 times as high
in growing dogs as it was in adult dogs; the values fol-
lowed the dogs’ growth curve, and adult serum 
PIIINP concentrations were attained at approximately
10 to 12 months. These results are consistent with the
values reported in children8 and earlier results in
German Shepherd Dog puppies.26 The results of the pre-
sent study indicated that not only the mean serum 
PIIINP concentration but also the mean BALF PIIINP
concentration was significantly higher in healthy grow-
ing dogs than in healthy adult dogs, thus underlining
the fact that the amount of PIIINP reflects the extent of
collagen turnover during growth. The naturally higher
concentrations of PIIINP detected in serum and BALF
samples from dogs during growth might limit the use of
PIIINP as a marker of pathologic fibrosis in growing
individuals because high PIIINP concentrations may
mask any alteration related to disease.
In the present study, serum PIIINP concentration
was negatively correlated with age. This finding is
intriguing because the opposite seems to be true in
humans. In humans, a slight increase of serum PIIINP
concentration after the age of 50 has been reported.27
We also identified a positive correlation of serum 
PIIINP concentration with body weight. This correla-
tion was highly significant and confirmed via multiple
linear regression analysis after adjustment for age. In
humans, changes in serum PIIINP concentration
reflect an increased collagen turnover in response to
increases in concentrations of growth hormone and
IGF-I; serum PIIINP concentration has been proposed
as a marker for monitoring the response to growth
hormone therapy in growth hormone–deficient chil-
dren,28 as well as for detection of growth hormone
abuse in athletes.29 In dogs, serum IGF-I concentration
is significantly correlated with weight30; therefore,
high serum PIIINP concentration might reflect higher
IGF-I concentrations in large-breed dogs. To the
authors’ knowledge, no relationship between body
size and serum PIIINP concentration in humans has
been reported, but there is a positive correlation
between serum PIIINP concentration and weight in
healthy obese people. Interestingly, serum PIIINP con-
centration decreases during weight loss in these indi-
viduals.31 The influence of obesity on serum PIIINP
concentration in dogs has not been addressed so far
but merits further investigation.
Compared with weight- and age-matched control
dogs, serum PIIINP concentration in dogs with DVD,
CMP, or CRF did not differ significantly; similarly, val-
ues in dogs with CBP and healthy control dogs did not
differ. These negative results have not yet been
explained, but could be attributable to several factors
given that serum PIIINP concentration depends not
only on collagen type III production by the tissue of
origin but also on the rate of release of the propeptide
into the bloodstream and its clearance by the liver.32
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A limitation of the present study is the fact that
organ fibrosis was not confirmed by histologic exami-
nation of tissue biopsy specimens, which is considered
the gold standard for evaluation of tissue fibrosis.
Biopsy specimens of myocardial, renal, and pulmonary
parenchyma were not obtained because of the inva-
siveness of those procedures and the fact that PIIINP
was studied in a population that included hospital
patients. It is a well-known fact that fibrosis is not an
inevitable feature of heart disease because the patterns
of myocardial remodeling are variable according to the
underlying disease process.33 Although myocardial
fibrosis has been associated with volume overload by
some authors,34 there is convincing evidence that
myocardial fibrosis is rather a minor feature in myocar-
dial remodeling secondary to volume overload.35 This
could in fact explain why serum PIIINP concentrations
were within reference range in dogs with cardiac insuf-
ficiency secondary to DVD (leading to volume over-
load), but not in the group of dogs with CMP.
However, in BALF, mean PIIINP concentration was
significantly higher in dogs with CBP, compared with
healthy adult control dogs. In the present study, most of
the dogs with CBP had eosinophilic BP, a disease charac-
terized by eosinophilic infiltration of the pulmonary tis-
sue and bronchial mucosa that has been well described in
dogs.10,36 High activities of serine proteases and metallo-
proteinases have been reported in BALF of dogs with
eosinophilic BP and seem to be responsible for the exten-
sive destruction and remodeling of the pulmonary tis-
sue.37,38 The results of our study indicated that an
increased collagen type III turnover resulting from the
extensive pulmonary remodeling in this condition may be
well reflected by increased PIIINP concentrations in
BALF. Nevertheless, there was considerable overlap
between PIIINP concentrations in BALF of healthy and
diseased adult dogs. A few dogs had extremely high BALF
PIIINP concentrations. Whether BALF PIIINP concentra-
tion can be correlated to severity of BP still needs to be
determined. Growing dogs had significantly higher BALF
PIIINP concentrations, compared with adult dogs, reflect-
ing increased collagen type III turnover related to growth.
Our data suggest that the radioimmunoassay based
on human PIIINP is accurate and sufficiently precise
for measurement of canine PIIINP in serum and BALF.
In healthy adult dogs, serum PIIINP concentration
appears to be strongly positively correlated with weight
and mildly negatively correlated with age. Serum 
PIIINP concentration in dogs was not notably affected
by renal insufficiency, heart disease, or chronic pul-
monary disease, but high BALF PIIINP concentrations
were detected in dogs with CBP. We therefore believe
that BALF PIIINP concentration could be a promising
marker of lung disease and merits further investigation
in a larger population of dogs with various bron-
chopulmonary pathologies. However, the naturally
higher PIIINP concentrations in serum and BALF in
healthy growing dogs, compared with adult dogs,
might limit the usefulness of PIIINP as a marker of
fibrosis in these young animals.
a. BD Vacutainer Systems, Plymouth, UK.
b. Centrifuge Hettich EBA Universal II, Tuttlingen, Germany.
c. Eppendorf tubes, Eppendorf-Nethler-Hinz GmbH, Hamburg,
Germany.
d. UniQ PIIINP radioimmunoassay, Orion Diagnostics, Espoo,
Finland.
e. Phosphate-buffered saline solution (0.3 g of NaH2PO4, 1.1 g of
Na2HPO4, and 9.0 g of NaCl/L ad 1000 Aqua bidestilata), adjusted
with 1 N HCl or 1N NaOH to pH 7.4, Merck, Darmstadt, Germany.
f. Saline (0.9% NaCl) solution, Merck KgaA, Darmstadt, Germany.
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